Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News

siRNA drug safely halved LDL cholesterol in phase 3 ORION-11
- Author:
- Mitchel L. Zoler, PhD
PARIS – The new drug inclisiran potently cut LDL cholesterol by inhibiting the PCSK9 enzyme with biannual...
Video

DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug
- Author:
- Mitchel L. Zoler, PhD
PARIS – Proof that dapagliflozin significantly helped heart failure patients without diabetes recategorizes the...
News

FDA’s low-risk TAVR okay set to propel case volume
- Author:
- Mitchel L. Zoler, PhD
The FDA’s approval of TAVR for low-risk patients should boost both case numbers and U.S. TAVR sites.
News

Ubrogepant shows acute migraine efficacy in triptan nonresponders
- Author:
- Mitchel L. Zoler, PhD
PHILADELPHIA – Data from two ubrogepant pivotal trials showed similar migraine pain relief in triptan-ineffective and triptan-effective patients...
News

Asthma hospitalization in kids linked with doubled migraine incidence
- Author:
- Mitchel L. Zoler, PhD
PHILADELPHIA – Data from 11 million U.S. pediatric inpatients showed a doubled rate of migraine diagnoses among kids hospitalized for asthma.
Video

Quarterly intravenous eptinezumab prevents migraine
- Author:
- Mitchel L. Zoler, PhD
PHILADELPHIA – Results from a pair of dose-ranging, randomized studies showed one IV eptinezumab dose cut migraine recurrences for 3 months.
News

FDA advisors recommend nintedanib for SSc interstitial lung disease
- Author:
- Mitchel L. Zoler, PhD
The positive outcome in nintedanib’s pivotal trial and prior FDA approval for idiopathic pulmonary fibrosis swayed panel members.
News

Atogepant shows safety, efficacy for migraine prevention
- Author:
- Mitchel L. Zoler, PhD
PHILADELPHIA – Atogepant is the first drug from its small-molecule class to undergo advanced clinical testing for migraine prevention.
News

Lymphoma risk prompts FDA recall of Allergan’s textured breast implants
- Author:
- Mitchel L. Zoler, PhD
The FDA asked Allergan to recall six brands of textured breast implants and expanders because of the lymphoma risk they pose.
News

Moderately high dietary riboflavin linked to fewer migraines
- Author:
- Mitchel L. Zoler, PhD
U.S. NHANES data showed a significant link between moderately high dietary vitamin B2 and fewer...
News

Medication overuse prevalent among U.S. migraine patients
- Author:
- Mitchel L. Zoler, PhD
PHILADELPHIA – Results from a U.S. survey showed an 18% prevalence of medication overuse among people with self-reported migraine symptoms.
Video

Overreliance on DAS scores undermines rheumatoid arthritis management
- Author:
- Mitchel L. Zoler, PhD
MADRID – A rheumatoid arthritis patient says “DAS blindness” now pervades rheumatoid arthritis management and degrades care.
News

Perioperative scripts for migraine abortive drugs linked with fewer pain readmissions
- Author:
- Mitchel L. Zoler, PhD
PHILADELPHIA - Migraine patients who underwent any surgery and then received a prescription for a migraine abortive drug had fewer 30-day pain...
Video

Telemedicine migraine consults are as effective as in-office visits
- Author:
- Mitchel L. Zoler, PhD
PHILADELPHIA - Follow-up telemedicine consultations with migraine patients produced outcomes similar to patients managed in office in a randomized...
News

Migraine comorbidities rise with increased headache days
- Author:
- Mitchel L. Zoler, PhD
PHILADELPHIA – As the number of migraine headache days per month rises, the prevalence of comorbidities like insomnia and depression also increase...